Cocrystal comprising camostat and niclosamide, pharmaceutical composition comprising same and preparation method therefor

A pharmaceutical composition for treating one or more cancer selected from the group consisting of pancreatic cancer, breast cancer, non-small cell lung cancer and liver cancer, comprising, as an active ingredient, a cocrystal comprising camostat or a pharmaceutically acceptable salt thereof, and niclosamide,

• (i) wherein a powder X-ray diffraction (XRD) pattern of the cocrystal includes diffraction peaks represented at diffraction angle 2θ (±0.2°) values of 5.37715°, 15.1122°, 18.2258°, 18.7579°, 20.3344°, 25.596° and 26.069°;
• and wherein when the heating rate is 10° C./min, a differential scanning calorimetry (DSC) endothermic peak of the cocrystal is shown at 144.38±3° C.;
• (ii) wherein a powder X-ray diffraction (XRD) pattern of the cocrystal includes diffraction peaks represented at diffraction angle 2θ (±0.2°) values of 6.55954°, 10.7176°, 18.147°, 19.5855°, 21.3591°, and 26.8178°;
• and wherein when the heating rate is 10° C./min, a differential scanning calorimetry (DSC) endothermic peak of the cocrystal is shown at 126.35±3° C.;
• (iii) wherein a powder X-ray diffraction (XRD) pattern of the cocrystal includes diffraction peaks represented at diffraction angle 2θ (±0.2°) values of 11.3876°, 16.0975°, 16.6493°, 18.679°, 23.0539°, 23.9013°, 24.4333°, and 29.7344°;
• and wherein when the heating rate is 10° C./min, a differential scanning calorimetry (DSC) endothermic peak of the cocrystal is shown at 182.74±3° C.;
• or
• (iv) wherein a powder X-ray diffraction (XRD) pattern of the cocrystal includes diffraction peaks represented at diffraction angle 2θ (±0.2°) values of 6.81572°, 7.46604°, 9.87023°, 12.3532°, 13.24°, and 18.6396°;
• and wherein when the heating rate is 10° C./min, a differential scanning calorimetry (DSC) endothermic peak of cocrystal is shown at 151.69±3° C.